Malcolm McColl
Chief Executive Officer at Viralytics Ltd.
Malcolm McColl active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Viralytics Ltd. | Chief Executive Officer | 2012-12-31 | - |
ImmVirX Pty Ltd.
 ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Chief Executive Officer | 2018-12-31 | - |
| Chairman | 2021-08-03 | - | |
| Founder | 2018-12-31 | - |
Career history of Malcolm McColl
Former positions of Malcolm McColl
| Companies | Position | Start | End |
|---|---|---|---|
Mayne Pharma, Inc.
 Mayne Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mayne Pharma, Inc. develops pharmaceutical products. Its services include pharmaceutical development, clinical trial materials, method development and validation, trace metals, stability, and microbiology services. The company was founded in 1994 and is headquartered in Greenville, NC. | Corporate Officer/Principal | 2006-12-31 | 2009-12-31 |
| VIRALYTICS LTD. | Director/Board Member | 2013-01-20 | - |
| Chief Executive Officer | 2013-01-20 | - | |
| Investor Relations Contact | - | - | |
| STARPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | 2011-01-03 | - |
Training of Malcolm McColl
| Melbourne Business School | Masters Business Admin |
| University of Melbourne | Undergraduate Degree |
Statistics
International
| Australia | 7 |
| United States | 2 |
Operational
| Chief Executive Officer | 3 |
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| STARPHARMA HOLDINGS LIMITED | Health Technology |
| Private companies | 4 |
|---|---|
Viralytics Pty Ltd.
 Viralytics Pty Ltd. BiotechnologyHealth Technology Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia. | Health Technology |
Mayne Pharma, Inc.
Mayne Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mayne Pharma, Inc. develops pharmaceutical products. Its services include pharmaceutical development, clinical trial materials, method development and validation, trace metals, stability, and microbiology services. The company was founded in 1994 and is headquartered in Greenville, NC. | Health Technology |
| Viralytics Ltd. | |
ImmVirX Pty Ltd.
ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Commercial Services |
- Stock Market
- Insiders
- Malcolm McColl
- Experience
